EXCIVA
exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using such compositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses.
EXCIVA
Industry:
Health Care Pharmaceutical
Founded:
2015-01-01
Address:
Heidelberg, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.exciva.com
Total Employee:
1+
Status:
Active
Total Funding:
10.44 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Font Awesome Apache Mobile Non Scaleable Content Euro Microsoft Exchange Online Office 365 Mail
Current Advisors List
Board_member
2021-10-01
Board_member
2021-10-01
Board_member
Board_member
2021-10-01
Current Employees Featured
Sreenivasarao Vepachedu Co-Founder @ Exciva
Co-Founder
2015-01-01
Mirko Scherer Acting CFO @ Exciva
Acting CFO
Anton Bespalov Co-founder, CMO & CSO @ Exciva
Co-founder, CMO & CSO
François Conquet CEO @ Exciva
CEO
2019-06-01
Founder
Investors List
Andera Partners
Andera Partners investment in Series A - Exciva
LBBW VC
LBBW VC investment in Series A - Exciva
Cure8 Ventures
Cure8 Ventures investment in Series A - Exciva
Andera Partners
Andera Partners investment in Seed Round - Exciva
Official Site Inspections
http://www.exciva.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Exciva"
About us | Exciva Gmbh
Established in 2016 in Heidelberg (Germany), EXCIVA is a privately held biotech company focused on developing clinical stage therapeutics for various indications in neuropsychiatry. …See details»
Exciva - Crunchbase Company Profile & Funding
Exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been …See details»
Exciva 2025 Company Profile: Valuation, Funding & Investors
When was Exciva founded? Exciva was founded in 2016. Where is Exciva headquartered? Exciva is headquartered in Heidelberg, Germany. What is the size of Exciva? Exciva has 6 total …See details»
Exciva Company Profile - Office Locations, Competitors, Revenue
Exciva is a biopharmaceutical company delivering treatment to address symptoms of Alzheimer’s patients. It offers a product Deraphan that treats behavioral and psychological symptoms in …See details»
Exciva - Products, Competitors, Financials, Employees, …
Exciva is a biopharmaceutical company focused on developing therapies for neuropsychiatric symptoms of dementia, including Alzheimer's disease. The company's main objective is to …See details»
EXCIVA GmbH Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for EXCIVA GmbH of Heidelberg, Baden-Württemberg. Get the latest business insights from Dun & …See details»
Exciva - LBBW Venture Capital
Exciva GmbH is a Heidelberg-based biopharmaceutical company founded in 2016, applying a transformational approach for clinical care of Alzheimer’s disease that fully integrates molecular, behavioral and chemistry technologies.See details»
Exciva - VentureRadar
Exciva is a clinical stage biopharmaceutical company focused on delivering an innovative treatment to address symptoms of Alzheimer’s patients. Management members and external …See details»
Exciva GmbH - life-sciences-europe.com
Jul 10, 2019 More documents for Exciva GmbH [1] Exciva GmbH. (10/26/21). "Press Release: Exciva Raises €9 Million in Series A Round Led by Andera Partners". Heidelberg.... To …See details»
Our science | Exciva Gmbh
Exciva's lead project is built upon two innovative drug development approaches targeting the symptomatic management of Alzheimer’s disease dementia that have recently emerged after decades of preclinical and clinical research .. …See details»
EXCIVA GmbH | CipherBio
Explore EXCIVA GmbH's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Exciva - Medtech Alert
Oct 26, 2021 EXCIVA GmbH. TARGETED DRUG RESCUE (TDR) There are about 3,000 drugs that have been approved by at least one country in this world. Just a handful of drugs received …See details»
Exciva - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Oct 26, 2021: Series A - Exciva …See details»
Andera Partners supports Exciva in a Series A to fight Alzheimer's ...
Oct 26, 2021 Andera Partners – a leading private equity player – through its biotech and medtech activity Andera Life Sciences, is leading the €9 million Series A round of Exciva …See details»
News | Exciva Gmbh
Oct 26, 2021 November 4, 2024. Our lead program, EXV-802 for the treatment of agitation in dementia associated with Alzheimer’s disease, received a Fast Track designation from the US …See details»
Exciva - Contacts, Employees, Board Members, Advisors & Alumni
German company is a provider of targeted drug rescue program intended to involve pharmaceutical research and development.See details»
Exciva Raises €9M in Series A Funding - FinSMEs
Oct 26, 2021 Exciva GmbH, a Heidelberg, Germany-based clinical biotech company developing a novel therapeutic compound for treating agitation/aggression in Alzheimer’s disease, closed …See details»
€9 million to address ‘Agitation/Aggression’ in Alzheimer’s
Oct 28, 2021 Exciva has closed a Series A financing of €9 million, led by Andera Partners, to develop the lead compound up to completion of Phase I. The product has the potential to treat …See details»
Home old | Exciva Gmbh
Our mission is to develop a groundbreaking therapy that effectively and safely addresses neuropsychiatric symptoms of dementia including agitation/aggression in Alzheimer’s disease …See details»
Expanded access policy | Exciva Gmbh
Exciva is currently developing an investigational product (EXV-802) for potential treatment for agitation in people with Alzheimer’s Disease. Exciva understands that there may be people …See details»